Peripheral Vascular Devices – Market Insights – Europe

The European PV device market will grow modestly over the forecast period, driven by increasing adoption of drug-eluting products as more clinical evidence for these technologies emerges, rising procedure volumes for iliac and lower limb indications, and the increasing adoption of endovascular techniques over surgical intervention. However, revenue growth will be limited to some extent by increasing price competition and ongoing cost constraints coupled with unfavorable reimbursement policies.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for PV devices in Europe from 2019 through 2032.

Uptake of drug-eluting technologies will drive growth in the market.

To what degree will DES and DCBs be adopted in Europe over the forecast period? How will adoption affect use of other PV stents or PTA balloons, respectively?

What are current perceptions of paclitaxel-coated devices in Europe?

What impact will the recent FDA letter concerning paclitaxel-based devices have on device choice in Europe?

What clinical outcomes have been generated in clinical trials for drug-eluting technologies?

Developments in endovascular interventions are focusing on treating the lower extremities.

How has this focus impacted the PV device market?

How has this affected the pipeline of European competitors?

Will DCBs or DES become the standard drug-eluting solution for BTK lesions?

M&A activities or partnerships involving key competitors may lead to shifts in market shares going forward.

Which acquisitions have occurred, and how will these acquisitions impact competitor performance in the future?

How are competitors leveraging product portfolio acquisitions to expand their product offerings?

Budgetary constraints and insufficient reimbursement in some segments continue to affect the European PV device market.

To what extent will lack of reimbursement affect to the adoption of premium-priced devices?

Which products are most impacted by reimbursement limitations?

How can companies mitigate these limiting factors?

Table of contents